Comprehensive genomic studies have delineated key driver mutations linked to disease
progression for most cancers. However, corresponding transcriptional changes remain …

How prostate cancer cells and their precursors mediate changes in the tumor
microenvironment (TME) to drive prostate cancer progression is unclear, in part due to the …

Prostate cancer displays considerable clinical, morphological, and biological heterogeneity.
Classical genetic techniques have provided only limited information about the pathogenesis …

Increasing evidence suggests the presence of minor cell subpopulations in prostate cancer
that are androgen independent and poised for selection as dominant clones after androgen …

Prostate cancer is a leading cause of global cancer-related death but attempts to improve
diagnoses and develop novel therapies have been confounded by significant patient …

Background Genomic analyses of hundreds of prostate tumors have defined a diverse
landscape of mutations and genome rearrangements, but the transcriptomic effect of this …

Prostate cancer (PCa) is a genetically heterogeneous cancer entity that causes challenges
in pre-treatment clinical evaluation, such as the correct identification of the tumor stage …

Identifying the earliest somatic changes in prostate cancer can give important insights into
tumor evolution and aids in stratifying high-from low-risk disease. We integrated whole …

Prostate cancer is initially responsive to androgen ablation therapy and progresses to
androgen-unresponsive states that are refractory to treatment. The mechanism of this …

The identification of genes that contribute to the biological basis for clinical heterogeneity
and progression of prostate cancer is critical to accurate classification and appropriate …